NCT00358813View on ClinicalTrials.gov

Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 8, 2006

Primary Completion Date

August 22, 2008

Study Completion Date

August 22, 2008

Conditions
Vomiting
Interventions
DRUG

Casopitant

Casopitant oral tablets will be available with a dose of 50 milligrams.

Trial Locations (3)

32809

GSK Investigational Site, Orlando

33025

GSK Investigational Site, Miramar

55404

GSK Investigational Site, Minneapolis

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY